Axogen, Inc. Common Stock (AXGN) is a publicly traded Healthcare sector company. As of May 21, 2026, AXGN trades at $42.94 with a market cap of $2.23B and a P/E ratio of -67.85. AXGN moved -0.07% today. Year to date, AXGN is +34.41%; over the trailing twelve months it is +268.97%. Its 52-week range spans $9.22 to $45.83. Analyst consensus is strong buy with an average price target of $50.14. Rallies surfaces AXGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Axogen Reports 26.6% Q1 Revenue Growth to $61.5M, Guides $270M in 2026: Axogen posted Q1 revenue of $61.5 million, up 26.6% year-over-year, with adjusted EBITDA of $5.7 million and cash reserves of $103.6 million. Net loss widened to $19.6 million including a $16.8 million one-time charge, while 2026 revenue guidance targets at least $270 million with 74–76% gross margin.
| Metric | Value |
|---|---|
| Price | $42.94 |
| Market Cap | $2.23B |
| P/E Ratio | -67.85 |
| EPS | $-0.63 |
| Dividend Yield | 1.00% |
| 52-Week High | $45.83 |
| 52-Week Low | $9.22 |
| Volume | 32 |
| Avg Volume | 0 |
| Revenue (TTM) | $238.10M |
| Net Income | $-31.45M |
| Gross Margin | 75.01% |
7 analysts cover AXGN: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $50.14.